10-87933082-T-C
Variant summary
Our verdict is Pathogenic. The variant received 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000314.8(PTEN):c.323T>C(p.Leu108Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 13/22 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L108R) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000314.8 missense
Scores
Clinical Significance
Conservation
Publications
- Cowden syndrome 1Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Ambry Genetics, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P
- PTEN hamartoma tumor syndromeInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- macrocephaly-autism syndromeInheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Ambry Genetics, Genomics England PanelApp, Orphanet
- renal cell carcinomaInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- leiomyosarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- activated PI3K-delta syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Bannayan-Riley-Ruvalcaba syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Cowden diseaseInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Lhermitte-Duclos diseaseInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Proteus-like syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- glioma susceptibility 2Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 19 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| PTEN | NM_000314.8 | c.323T>C | p.Leu108Pro | missense_variant | Exon 5 of 9 | ENST00000371953.8 | NP_000305.3 | |
| PTEN | NM_001304718.2 | c.-428T>C | 5_prime_UTR_premature_start_codon_gain_variant | Exon 4 of 9 | NP_001291647.1 | |||
| PTEN | NM_001304717.5 | c.842T>C | p.Leu281Pro | missense_variant | Exon 6 of 10 | NP_001291646.4 | ||
| PTEN | NM_001304718.2 | c.-428T>C | 5_prime_UTR_variant | Exon 4 of 9 | NP_001291647.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Not observed at significant frequency in large population cohorts (gnomAD); Published functional studies demonstrate a damaging effect: inability to reduce pAKT levels and impaired lipid phosphatase activity (PMID: 29706350, 25527629); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 29043291, 29785012, 25527629, 17526801, 23399955, 20712882, 29706350, 32885271, 24475377) -
- -
Cowden syndrome 1 Pathogenic:1
This variant is considered pathogenic. Functional studies indicate this variant impacts protein function [PMID: 25527629, 29785012]. This variant is expected to disrupt protein structure [PMID: 27405757]. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 17526801, 29043291]. -
PTEN hamartoma tumor syndrome Pathogenic:1
Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (Invitae) indicates that this missense variant is expected to disrupt PTEN function. For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects PTEN function (PMID: 25527629). ClinVar contains an entry for this variant (Variation ID: 418436). This missense change has been observed in individuals with Cowden syndrome (PMID: 17526801, 20712882, 23399955, 29043291). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 108 of the PTEN protein (p.Leu108Pro). -
Malignant tumor of breast Pathogenic:1
The PTEN p.Leu108Pro variant was identified in the literature, however the frequency of this variant in an affected population was not provided. The variant was also identified in dbSNP (ID: rs1064793243) as "With Pathogenic allele", ClinVar (classified as pathogenic by GeneDx, Invitae and Mayo Clinic; as likely pathogenic by Ambry Genetics), and LOVD 3.0 database (2x). The variant was not identified in the following control databases: the Exome Aggregation Consortium (August 8th 2016) or the Genome Aggregation Database (Feb 27, 2017). This variant has been observed in a number of individuals with Cowden syndrome or Cowden syndrome-like phenotypes, including patients with breast cancer, macrocephaly, ovarian granulosa cell tumour, endometrial cancer, thyroid carcinoma, polyposis and Schwann cell hamartoma of the colon (Nizialek 2015, Tan 2007, Ngeow 2013, Banneau 2010, Anderson 2017). Multiple studies demonstrated that this variant results in a significantly reduced protein expression level and may also result in failure to downregulate AKT phosphorylation (Spinelli 2014, Gupta 2016). The p.Leu108 residue is conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more pathogenic role for this variant. This variant is classified as likely pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.L108P variant (also known as c.323T>C), located in coding exon 5 of the PTEN gene, results from a T to C substitution at nucleotide position 323. The leucine at codon 108 is replaced by proline, an amino acid with similar properties. This alteration has been observed in multiple individuals with a personal and/or family history that is consistent with PTEN hamartoma tumor syndrome (Tan WH et al. J Med Genet, 2007 Sep;44:594-602; Banneau G et al. Breast Cancer Res, 2010 Aug;12:R63; Ngeow J et al. Gastroenterology, 2013 Jun;144:1402-9, 1409.e1-5; Anderson B et al. ACG Case Rep J, 2017 Oct;4:e113). In a massively parallel functional assay using a humanized yeast model, lipid phosphatase activity for this variant was functionally deficient (Mighell TL et al. Am J Hum Genet, 2018 05;102(5):943-955). Furthermore, this variant demonstrated low intracellular protein abundance on one multiplex functional assay (Matreyek KA et al. Nat Genet, 2018 06;50:874-882). This amino acid position is highly conserved in available vertebrate species. This missense alteration is located in a region that has a low rate of benign missense variation (Lek M et al. Nature, 2016 Aug 18;536(7616):285-91; DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources. Firth H.V. et al. 2009. Am J Hum Genet, 84, 524-533 (DOI: dx.doi.org/10/1016/j.ajhg.2009.03.010)). In addition, this variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at